New York, New York--(Newsfile Corp. - February 10, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation (NYSE: BSX) ("Boston Scientific Corporation") concerning potential violations of the federal securities laws.On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results. While the company exceeded analyst expectations for earnings per share and total revenue, its electrophysiology segment reported sales of $890 million, appr ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Boston Scientific Corporation ("Boston Scientific†or the "Company†) (NYSE: BSX) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BOSTON SCIENTIFIC CORPORATION (BSX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER Y. ...

Core Viewpoint - Boston Scientific Corporation is under investigation for potential violations of federal securities laws following its fourth-quarter 2025 earnings report, which revealed a significant shortfall in its electrophysiology segment sales compared to market expectations [1][5]. Financial Performance - Boston Scientific reported fourth-quarter 2025 earnings, exceeding analyst expectations for earnings per share and total revenue, but its electrophysiology segment sales were $890 million, approximately $43 million below the consensus estimate of $933 million [2]. - The company had previously guided for organic growth of 11% to 13% for the fourth quarter, but management indicated confidence in only about 15% growth going forward, which is significantly lower than the market's expectation of approximately 25% [4][5]. Market Dynamics - The electrophysiology market is one of the fastest-growing areas in cardiovascular medicine, with pulsed field ablation technology emerging as a potential alternative to traditional thermal ablation procedures [3]. - Boston Scientific entered this market through its acquisition of Farapulse in 2021 and has made substantial investments in expanding manufacturing capacity and physician training programs [3]. Growth Projections - The company projected that global penetration of pulsed field ablation technology would reach 50% by the end of 2025 and grow to approximately 80% by 2028 [3]. - The company emphasized strong growth rates in its electrophysiology segment, reporting 94% growth in Q2 2025 and 63% growth in Q3 2025 [4]. Stock Market Reaction - Following the earnings release, Boston Scientific's shares fell by 17.5%, reaching a 52-week low of $75.50, indicating a negative market reaction to the earnings report and growth outlook [5].

以下文章来源于AI医疗观察 ，作者关注AI医疗的 AI医疗观察 . 响应《关于深入实施"人工智能+"行动的意见》，推动AI在医疗领域的应用，本账号发布权威资讯 在手术室的角落里，一个 AI引擎正以每秒千次的速度，审阅着全球数万份临床报告，将美敦力一款新心脏起搏器的上市时间悄悄提前了半年；在 GE医疗的全球仓库中，无形的算法网络正实时调度着数万种零部件，悄然锁定了数亿美元本会闲置的现金。 这些没有发布会、不产生炫目 DEMO的"静默革命"，正在成为2026年全球医疗科技领域真正的资本主线。摩根士丹利、贝恩等顶级机构在开年密 集发出报告，核心指向一个颠覆性趋势：聪明的钱，正急速从追逐"AI医疗初创公司"的喧嚣中撤离，转而重仓那些正在用AI系统性改造自己、且 已看到惊人效率提升的传统医疗巨头——美敦力、直觉外科、GE医疗、波士顿科学。 一场由 "效率"定义的静默革命，正在成为2026年全球医疗科技领域真正的资本主线。其核心信号是： 聪明的钱，正急速从追逐 "纯AI工具"的喧 嚣中撤离，转而重仓那些正在用AI系统性改造自己、并能清晰证明效率提升的传统医疗巨头。 行业领袖们并非在产品上简单添加 AI模块，而是正在沿三条 ...

Core Viewpoint - Truist has lowered its price target for Boston Scientific Corporation (BSX) from $120 to $95 while maintaining a Buy rating, citing that the stock's recent pullback appears excessive given its current valuation compared to faster-growing peers [1] Financial Performance - Boston Scientific's earnings release on February 4 revealed weaker-than-expected results in its electrophysiology business, which is crucial for the company's growth narrative [2] - Fourth-quarter sales in the electrophysiology segment reached $890 million, missing analysts' expectations of $933 million [2] - The sales of the Watchman device, aimed at preventing strokes in patients with atrial fibrillation, were approximately 1% below forecasts, attributed to softer demand in the US market [3] - For the upcoming year, Boston Scientific projects adjusted earnings per share between $3.43 and $3.49, with the midpoint slightly below Wall Street's expectation of $3.47 [3] - Total revenue for the quarter was $5.29 billion, with adjusted earnings of 80¢ per share, both aligning closely with estimates [3] Future Outlook - The company anticipates organic revenue growth of 10% to 11% by 2026, indicating a slowdown compared to the 15.8% organic growth reported in 2025 [4] - Boston Scientific develops and sells medical devices utilized in various interventional procedures globally [4]

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Boston Scientific Corporation ("Boston Scientific†or the "Company†) (NYSE: BSX) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BOSTON SCIENTIFIC CORPORATION (BSX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to disc. ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Boston Scientific Corporation ("Boston Scientific†or the "Company†) (NYSE: BSX) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BOSTON SCIENTIFIC CORPORATION (BSX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On February 4, 2026, Boston Scientific. ...

Core Insights - Edwards Lifesciences and Boston Scientific both demonstrated strong quarterly performance, indicating robust demand in the heart device market [1] Company Strategies - Edwards Lifesciences and Boston Scientific are employing fundamentally different strategies within the heart device sector, which may impact their future growth trajectories [1]

Austin, United States, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Surgical Staplers Market Size & Growth Analysis: According to SNS Insider, The Surgical Staplers Market was valued at USD 6.41 billion in 2025 and is projected to reach USD 10.87 billion by 2033, growing at a CAGR of 6.87% during the forecast period 2026-2033. The global burden of chronic diseases that require surgical intervention, rising surgical procedure volumes, and the growing acceptance of minimally invasive and laparoscopic surgeries are all f ...

Core Viewpoint - Boston Scientific Corporation is experiencing strong financial performance, leading to optimistic price targets from analysts, particularly Needham, who set a target of $97, indicating a potential increase of approximately 28.44% from the current trading price of $75.52 [2][6]. Financial Performance - Boston Scientific reported fourth-quarter revenues of $5.29 billion, slightly surpassing the consensus estimate of $5.28 billion [2][6]. - The adjusted earnings per share for the fourth quarter were 80 cents, exceeding both the consensus estimate of 78 cents and the management's guidance of 77 to 79 cents [3][6]. Growth Outlook - The company forecasts net sales growth of approximately 10.5% to 11.5% in 2026 on a reported basis, and 10% to 11% organically [4]. - Expected sales for 2026 are projected to be between $22.18 billion and $22.38 billion, aligning closely with the consensus of $22.37 billion [4][6]. Market Reaction - Following the earnings announcement, BSX shares rose by 0.6% to $75.92 in pre-market trading, although the stock is currently priced at $75.45, reflecting a slight decrease of approximately 0.07% [5]. - The company's market capitalization remains robust at approximately $111.9 billion, indicating strong investor confidence [5].